Warburg effect revisited: An epigenetic link between glycolysis and gastric carcinogenesis

Oncogene

Volumn 29, Issue 3, 2010, Pages 442-450

  Liu, X ^a   Wang, X ^b   Zhang, J ^a   Lam, E K Y ^a   Shin, V Y ^a   Cheng, A S L ^a   Yu, J ^c   Chan, F K L ^c   Sung, J J Y ^c   Jin, H C ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b ZHEJIANG UNIVERSITY   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Gastric cancer; Glucose metabolism; Methylation; Ras

Indexed keywords

FRUCTOSE 1,6 BISPHOSPHATASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATASE; RAS PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; DEMETHYLATION; DOWN REGULATION; EPIGENETICS; GLYCOLYSIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; STOMACH CANCER; WALKER WARBURG SYNDROME;

AGED; ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; DOWN-REGULATION; EPIGENESIS, GENETIC; FEMALE; FRUCTOSE-BISPHOSPHATASE; GLUCOSE; GLYCOLYSIS; HUMANS; KAPLAN-MEIERS ESTIMATE; LACTIC ACID; MALE; MICE; MIDDLE AGED; NF-KAPPA B; NIH 3T3 CELLS; PROGNOSIS; PROMOTER REGIONS, GENETIC; RAS PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; STOMACH NEOPLASMS;

EID: 75149159101     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.332     Document Type: Article

References (36)

1. Aarenstrup L, Flindt EN, Otkjaer K, Kirkegaard M, Andersen JS, Kristiansen K. (2008). HDAC activity is required for p65/RelA-dependent repression of PPARdelta-mediated transactivation in human keratinocytes. J Invest Dermatol 128: 1095-1106.
2. Ashburner BP, Westerheide SD, Baldwin Jr AS. (2001). The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol 21: 7065-7077.
3. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R et al. (2006). TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126: 107-120.
4. Bhat KP, Pelloski CE, Zhang Y, Kim SH, deLaCruz C, Rehli M et al. (2008). Selective repression of YKL-40 by NF-kappaB in glioma cell lines involves recruitment of histone deacetylase-1 and-2. FEBS Lett 582: 3193-3200.
5. Cheng YY, Jin H, Liu X, Siu JM, Wong YP, Ng EK et al. (2008). Fibulin 1 is downregulated through promoter hypermethylation in gastric cancer. Br J Cancer 99: 2083-2087.
6. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R et al. (2008). The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452: 230-233.
7. Dang CV, Semenza GL. (1999). Oncogenic alterations of metabolism. Trends Biochem Sci 24: 68-72.
8. DeBerardinis RJ. (2008). Is cancer a disease of abnormal cellular metabolism? New angles on an old idea. Genet Med 10: 767-777.
9. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. (2008a). The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7: 11-20.
10. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. (2008b). Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 18: 54-61.
11. Eigenbrodt E, Reinacher M, Scheefers-Borchel U, Scheefers H, Friis R. (1992). Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. Crit Rev Oncog 3: 91-115.
12. Ferguson EC, Rathmell JC. (2008). New roles for pyruvate kinase M2: working out the Warburg effect. Trends Biochem Sci 33: 359-362.
13. Finco TS, Westwick JK, Norris JL, Beg AA, Der CJ, Baldwin Jr AS. (1997). Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation. J Biol Chem 272: 24113-24116.
14. Fuks F, Burgers WA, Brehm A, Hughes-Davies L, Kouzarides T. (2000). DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet 24: 88-91.
15. Garber K. (2004). Energy boost: the Warburg effect returns in a new theory of cancer. J Natl Cancer Inst 96: 1805-1806.
16. Gatenby RA, Gillies RJ. (2004). Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891-899.
17. Green DR, Chipuk JE. (2006). p53 and metabolism: inside the TIGAR. Cell 126: 30-32.
18. Jin H, Sperka T, Herrlich P, Morrison H. (2006). Tumorigenic transformation by CPI-17 through inhibition of a merlin phospha-tase. Nature 442: 576-579.
19. Jurica MS, Mesecar A, Heath PJ, Shi W, Nowak T, Stoddard BL. (1998). The allosteric regulation of pyruvate kinase by fructose-1,6-bisphosphate. Structure 6: 195-210.
20. Karnoub AE, Weinberg RA. (2008). Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 9: 517-531.
21. Kawauchi K, Araki K, Tobiume K, Tanaka N. (2008). p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol 10: 611-618.
22. Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, Peters G et al. (2005). Glycolytic enzymes can modulate cellular life span. Cancer Res 65: 177-185.
23. Koshiba M, Ogawa O, Habuchi T, Hamazaki S, Shimada T, Takahashi R et al. (1993). Infrequent ras mutation in human stomach cancers. Jpn J Cancer Res 84: 163-167.
24. Lee MG, Pedersen PL. (2003). Glucose metabolism in cancer: importance of transcription factor-DNA interactions within a short segment of the proximal region og the type II hexokinase promoter. J Biol Chem 278: 41047-41058.
25. Marin-Hernandez A, Rodriguez-Enriquez S, Vital-Gonzalez PA, Flores-Rodriguez FL, Macias-Silva M, Sosa-Garrocho M et al. (2006). Determining and understanding the control of glyco-lysis in fast-growth tumor cells. Flux control by an over-expressed but strongly product-inhibited hexokinase. FEBS J 273: 1975-1988.
26. Mathupala SP, Ko YH, Pedersen PL. (2008). Hexokinase-2 bound to mitochondria: cancer's stygian link to the 'Warburg Effect' and a pivotal target for effective therapy. Semin Cancer Biol 19: 17-24.
27. Mazurek S, Zwerschke W, Jansen-Durr P, Eigenbrodt E. (2001). Metabolic cooperation between different oncogenes during cell transformation: interaction between activated ras and HPV-16 E7. Oncogene 20: 6891-6898.
28. Peng SY, Lai PL, Pan HW, Hsiao LP, Hsu HC. (2008). Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis. Oncol Rep 19: 1045-1053.
29. Robertson KD, Ait-Si-Ali S, Yokochi T, Wade PA, Jones PL, Wolffe AP. (2000). DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet 25: 338-342.
30. Rountree MR, Bachman KE, Baylin SB. (2000). DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet 25: 269-277.
31. Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E. (2004). The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res 64: 2627-2633.
32. Tannock IF. (1968). The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour. Br J Cancer 22: 258-273.
33. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. (1996). Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 274: 787-789.
34. Vaupel P, Kallinowski F, Okunieff P. (1989). Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49: 6449-6465.
35. Wang LJ, Jin HC, Wang X, Lam EK, Zhang JB, Liu X et al. (2009). ZIC1 is downregulated through promoter hypermethylation in gastric cancer. Biochem Biophys Res Commun 379: 959-963.
36. Warburg O. (1956). On the origin of cancer cells. Science 123: 309-314.